Navigation Links
CeloNova BioSciences Announces World's First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
Date:9/8/2007

ATLANTA, Sept. 8 /PRNewswire/ -- CeloNova BioSciences, Inc. ("CeloNova"), a leading developer of innovative medical devices, today unveiled the world's first fully color-coded line of embolic particles, Embozene(TM) Color-Advanced Microspheres, at the annual meeting of the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) in Athens, Greece.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070908/CLSA008 )

Embolic microspheres are used to treat liver cancer, fibroids, and other hypervascularized tumors. "With the release of Color-Advanced Microspheres, interventional radiologists now have available a highly biocompatible, precisely calibrated embolic particle that offers the unique safety and convenience advantages of being color coded by microsphere size. Nothing else on the embolic market offers such a compelling package of superior clinical performance combined with total ease-of-use for the physician," stated CeloNova President and Chief Executive Officer Thomas A. Gordy.

Ranging in size from 40 microns (approximately the diameter of a human hair) to 900 microns and based on the company's already well-received opaque microspherical product, Embozene(TM) Color-Advanced Microspheres now offer the additional benefit of enhanced visibility and instant, effortless identification of microsphere size by color. This means:

-- Immediate visual confirmation that the microspheres are properly mixed

before injection;

-- Reduced risk of cross-contamination during the procedure;

-- A reduced risk of injecting too many or too few microspheres because

they are clearly visible;

-- No more waste due to uncertainty when a physician is operating with

multiple microsphere sizes.

Gordy continued: "From the beginning, CeloNova has operated on the principle that our products would be designed with class-leading
'/>"/>

SOURCE CeloNova BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Theravalues Corporation annuncia con orgoglio il lancio di Theracurmin® ... Europe 2014 (dal 2 al 4 dicembre, ... con la maggiore biodisponibilità di sempre, con una combinazione ... norme europee. La curcumina è un pigmento ... longa ) che è stata associata con attività antiossidanti, ...
(Date:11/24/2014)... Belgium , Nov. 24, 2014 ... focused on developing diagnostic tests for cancer and other conditions, ... will be presented at the Science for Business BioWin Day ... Belgium . The data come from VolitionRx,s lung cancer ... Pneumology department of the Centre Hospitalier Universitaire (CHU) de Liege ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 2014 ... Dihydrazide Industry is a professional and in-depth research ... Adipic Dihydrazide information, like its definition, classification, application, ... overview. This report covers the international market analysis, ... (such as the US, Europe, Asia, China, Japan ...
(Date:11/22/2014)... November 21, 2014 Two new educational webinars ... comes next for ALS research and how the pharmaceutical industry ... the Ice Bucket Challenge: Where Does the ALS Money Go? ... 2 December 2014, Time: 1:30pm ET, Register to ... speaker Dr. Merit Cudkowicz, Julianne Dorn Professor of Neurology at ...
Breaking Biology Technology:La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 2Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 3DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2
... Care Compliance Strategies, Inc. (HCCS) announced today a partnership ... to deliver a series of critical care nursing and ... Management Systems.  This training includes two separate AACN courses: ... Essentials of Nurse Manager Orientation . The courses ...
... Amsterdam Molecular Therapeutics (Euronext: AMT), a leader ... it has filed,a request for re-examination of the Marketing ... Agency.,Glybera is a gene therapy for the genetic disorder ... dossier will be completed by the end of 2011. ...
... combination of sophisticated computer modeling and advanced materials ... led by the University at Buffalo (UB) and ... (NIST), the Molecular Foundry at Lawrence Berkeley National ... simple processing flaws can seriously degrade the otherwise ...
Cached Biology Technology:HCCS Partners with American Association of Critical Care Nurses (AACN) to Offer Nurse Training 2HCCS Partners with American Association of Critical Care Nurses (AACN) to Offer Nurse Training 3Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination 2Graphene: What can go wrong? new studies point to wrinkles, process contaminants 2
(Date:11/4/2014)... November 4, 2014   ... growth   Fuel3D , a developer of ... funding round totaling $6.4 million (£4 million). This funding builds ... earlier this year and paves the way for the commercial ... The funding round was led by Chimera Partners and ...
(Date:11/3/2014)... , Nov. 3, 2014 Research and ... "Cell Therapy - Technologies, Markets and Companies" to ... cell therapy technologies and methods, which have already started to ... stem cell transplantation is replacing the old fashioned bone marrow ... Cell therapy is bound to become a part of medical ...
(Date:11/3/2014)... and preterm birth are linked to increased risk for ... the American College of Rheumatology (ACR) journal, Arthritis ... and pre-term babies were not at greater risk of ... According to the ACR, 27 million Americans over the ... of OA range from mild to severe and include ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3Preterm, low birth-weight babies may need new hips in adulthood 2
... when it made its first U.S. appearance in New ... coast to coast, sickened more than 16,000 Americans and ... investigators hastened research to develop an effective vaccine or ... by researchers at Washington University in St. Louis points ...
... made a significant advance toward understanding the regulation of ... blood cell formation. A research study published in the ... by using adult animals to examine the role of ... cell formation. Information gained from this research will be ...
... cloning and sequencing technique has identified a surprisingly high number ... the need for closer scrutiny of public hot pools, says ... Louis and involving the University of Colorado at Boulder and ... population in a warm hospital therapy pool through a ribosomal ...
Cached Biology News:Promising new West Nile therapy cures disease in mice 2New insight into regulation of blood stem cells 2New lab technique identifies high levels of pathogens in therapy pool 2New lab technique identifies high levels of pathogens in therapy pool 3
Integrins Sampler Kit 10g each...
PKC Sampler Kit 10 mu g each...
Golgi Sampler Kit 10g each...
Umbilical cord blood eosinophils, For immunohistochemistry (IHC)...
Biology Products: